Predicted coverage changes post-approval: Based on the coverage expansion pattern when Wegovy gained FDA approval for obesity in 2021, we expect: 60-70% of large-employer commercial plans to cover GLP-1s for NASH within 6 months of FDA approval 30-40% of marketplace plans to add coverage within 12 months Medicare Part D to cover for NASH (but not for obesity, due to the statutory weight-loss drug exclusion) Medicaid coverage to remain state-specific, with 15-20 states adding NASH coverage within 18 months Prior authorization will still be required, but approval rates will flip from 25% (current off-label rate) to 70-80% (typical for newly approved indications)
Ben Arous, J., Laffont, S
Generally, patients who remain completely asymptomatic for 6 hours after ingestion and have a normal physical examination do not require treatment for iron poisoning (Fig
Whether you need 6-month intensive treatment or long-term maintenance, PlexusDx licensed 503A compounded medications are accessible in all 50 states without insurance or membership fees, making any duration medically and financially manageable
Con fines didcticos hemos clasificado las lesiones pigmentadas como localizadas y difusas
The absorption and bioavailability with a GHK-Cu injection is dramatically higher than topical application, which means greater potential benefit AND a greater need for medical oversight
